Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 3/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219171 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL17101325 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1302931 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3050298 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL11753239 | 0.97 | TDP1 (0.71) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3761094 | 0.97 | TDP1 (0.71) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL6072946 | 0.97 | TDP1 (0.71) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL865783 | 0.90 | — | — | |
| SCHEMBL148513 | 0.90 | — | — | |
| SCHEMBL17101240 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130118986-A1 | High Capacity Oxoanion Chelating Media From Hyperbranched Macromolecules | NATIONAL SCIENCE FOUNDATION | 2013-05-16 | — | — | US | claimed |
| WO-1999021825-A1 | HYDROXY FATTY ACID SACCHARIDE AMIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1999-05-06 | — | — | WO | claimed |
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| CN-106103423-B | Pyrazine compounds | 阿斯利康(瑞典)有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| EP-3119752-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140527-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-09-24 | — | — | WO | disclosed |
| WO-1999021825-A1 | HYDROXY FATTY ACID SACCHARIDE AMIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | LMNA 4145/4885L3MBTL1 4746/4885TDP1 4701/4885 |
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | LMNA 4145/4885L3MBTL1 4746/4885TDP1 4701/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | LMNA 4145/4885L3MBTL1 4746/4885TDP1 4701/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | LMNA 4145/4885L3MBTL1 4746/4885TDP1 4701/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | LMNA 4145/4885L3MBTL1 4746/4885TDP1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.